Spitalul Judetean De Urgenta Dr. Constantin Opris Baia Mare
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Heart Failure Research
At Spitalul Judetean De Urgenta Dr. Constantin Opris Baia Mare, clinical research in cardiology is strongly centered on cardiovascular diseases, especially heart failure, atherosclerotic cardiovascular disease, and related complications. These studies are designed to evaluate new treatment approaches, reduce hospitalizations, and improve outcomes such as cardiovascular death and worsening heart failure.
- Studies in chronic and symptomatic heart failure are assessing whether new therapies can better prevent major cardiac events.
- Research is also examining treatments for patients with heart failure and impaired kidney function to improve overall disease control.
- Another area of focus is coronary inflammation after myocardial infarction, with the goal of better understanding and treating residual cardiovascular risk.
This work reflects a broad effort to improve both long-term management and event prevention in people with serious cardiac disease.
Neoplasms and Gastrointestinal Cancer Studies
The site is also involved in oncology research on several neoplasms, with a particular emphasis on colorectal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal cancer. These trials are focused on testing new treatment combinations and comparing them with existing cancer therapies to improve survival and disease control.
- Research includes advanced colorectal cancer with KRAS G12C mutation, aiming to find more effective treatment options after standard therapy.
- Studies in advanced gastric and gastroesophageal cancers are evaluating targeted and immunotherapy-based approaches.
- Additional work is exploring treatment for advanced non-small cell lung cancer, broadening the site’s cancer research portfolio.
Overall, this research aims to improve outcomes for patients with difficult-to-treat solid tumors through more precise and effective therapies.
Immune System Diseases and Rheumatology
Clinical trials in immune system diseases at this hospital include research in rheumatoid arthritis and related inflammatory conditions. The main purpose of this work is to compare treatment options and identify therapies that can better control inflammation while maintaining safety.
- Rheumatoid arthritis studies are evaluating newer medicines against established immune-targeted treatments.
- The research is aimed at improving symptom control and reducing disease activity in people with chronic inflammatory disease.
- These trials contribute to a better understanding of how immune-modulating therapies perform in routine clinical care.
This area adds an important rheumatology dimension to the site’s broader clinical research profile.
Respiratory Tract Diseases in Advanced Lung Cancer
Research in respiratory tract diseases at Spitalul Judetean De Urgenta Dr. Constantin Opris Baia Mare includes studies in advanced non-small cell lung cancer. These trials are intended to test new treatment strategies for patients whose disease has already been treated and continues to progress.
- The main focus is on improving survival and disease response in lung cancer.
- Studies are comparing investigational therapies with existing standard treatments to identify more effective options.
- This work supports ongoing progress in thoracic oncology and advanced cancer care.
The respiratory research portfolio is closely linked with cancer treatment, reflecting the site’s role in managing complex pulmonary malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Judetean De Urgenta Dr. Constantin Opris Baia Mare
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 3 | Unknown | 2021-11-30 | 2023-05-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
